InVivo Therapeutics Holdings PE Ratio 2010-2023 | NVIVQ
Current and historical p/e ratio for InVivo Therapeutics Holdings (NVIVQ) from 2010 to 2023. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. InVivo Therapeutics Holdings PE ratio as of September 17, 2024 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
InVivo Therapeutics Holdings PE Ratio Historical Data | |||
---|---|---|---|
Date | Stock Price | TTM Net EPS | PE Ratio |
2024-02-12 | 0.32 | 0.00 | |
2023-09-30 | 1.12 | $-0.87 | 0.00 |
2023-06-30 | 1.35 | $-1.98 | 0.00 |
2023-03-31 | 1.06 | $-3.95 | 0.00 |
2022-12-31 | 2.35 | $-5.89 | 0.00 |
2022-09-30 | 4.29 | $-8.14 | 0.00 |
2022-06-30 | 4.05 | $-7.91 | 0.00 |
2022-03-31 | 8.63 | $-7.94 | 0.00 |
2021-12-31 | 11.40 | $-6.00 | 0.00 |
2021-06-30 | 18.56 | $-15.50 | 0.00 |
2021-03-31 | 24.85 | $-26.00 | 0.00 |
2020-12-31 | 20.25 | $-85.75 | 0.00 |
2020-09-30 | 35.50 | $-85.75 | 0.00 |
2020-06-30 | 39.38 | $-75.75 | 0.00 |
2020-03-31 | 42.25 | $-281.22 | 0.00 |
2019-12-31 | 168.68 | $-474.72 | 0.00 |
2021-09-30 | 17.47 | $-684.93 | 0.00 |
2019-09-30 | 375.90 | $-683.18 | 0.00 |
2019-06-30 | 555.00 | $-780.78 | 0.00 |
2019-03-31 | 1162.50 | $-6,141.14 | 0.00 |
2018-12-31 | 1132.50 | $-8,438.44 | 0.00 |
2018-09-30 | 1515.00 | $-10,878.38 | 0.00 |
2018-06-30 | 1275.00 | $-15,818.32 | 0.00 |
2018-03-31 | 10031.25 | $-13,956.46 | 0.00 |
2017-12-31 | 14437.50 | $-15,202.70 | 0.00 |
2017-09-30 | 27187.50 | $-15,953.45 | 0.00 |
2017-06-30 | 50625.00 | $-14,264.27 | 0.00 |
2017-03-31 | 75937.50 | $-13,513.51 | 0.00 |
2016-12-31 | 78750.00 | $-14,264.26 | 0.00 |
2016-09-30 | 127499.99 | $-14,264.26 | 0.00 |
2016-06-30 | 108374.99 | $-12,387.39 | 0.00 |
2016-03-31 | 130874.99 | $-16,704.20 | 0.00 |
2015-12-31 | 134999.99 | $-24,211.71 | 0.00 |
2015-09-30 | 161624.99 | $-27,777.78 | 0.00 |
2015-06-30 | 302812.48 | $-26,839.34 | 0.00 |
2015-03-31 | 222749.99 | $-22,522.52 | 0.00 |
2014-12-31 | 99000.00 | $-15,765.77 | 0.00 |
2014-09-30 | 42000.00 | $-14,264.26 | 0.00 |
2014-06-30 | 78000.00 | $-18,768.77 | 0.00 |
2014-03-31 | 131999.99 | $-30,780.78 | 0.00 |
2013-12-31 | 172499.99 | $-40,540.53 | 0.00 |
2013-09-30 | 107249.99 | $-45,045.04 | 0.00 |
2013-06-30 | 309749.98 | $-31,531.52 | 0.00 |
2013-03-31 | 179249.99 | $-14,264.26 | 0.00 |
2012-12-31 | 130499.99 | $4,504.50 | 28.97 |
2012-09-30 | 116249.99 | $-36,786.79 | 0.00 |
2012-06-30 | 171749.99 | $-40,540.54 | 0.00 |
2012-03-31 | 185999.99 | $-45,045.04 | 0.00 |
2011-12-31 | 206249.99 | $-48,798.80 | 0.00 |
2011-09-30 | 49500.00 | $2,252.25 | 21.98 |
Sector | Industry | Market Cap | Revenue |
---|---|---|---|
Medical | Medical Products Manufacturing | $0.001B | $0.000B |
InVivo Therapeutics Holdings Corp. operates as a medical device company focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company intends to offer three products, including a biocompatible polymer scaffolding device to treat acute wound SCI; a biocompatible hydrogel for local controlled release of methylprednisolone to treat acute SCI; and a biocompatible polymer scaffolding device seeded with autologous hNSCs to treat acute and chronic SCI. InVivo Therapeutics Holdings Corp. is based in Cambridge, Massachusetts. |
Stock Name | Country | Market Cap | PE Ratio |
---|---|---|---|
Abbott Laboratories (ABT) | United States | $204.664B | 26.43 |
Stryker (SYK) | United States | $141.745B | 33.12 |
Boston Scientific (BSX) | United States | $122.979B | 37.45 |
Medtronic (MDT) | Ireland | $115.565B | 17.20 |
EssilorLuxottica (ESLOY) | France | $106.116B | 0.00 |
Haleon (HLN) | United Kingdom | $48.437B | 35.40 |
Lonza Group Ag (LZAGY) | Switzerland | $47.258B | 0.00 |
ResMed (RMD) | United States | $36.993B | 32.57 |
Koninklijke Philips (PHG) | Netherlands | $29.119B | 22.13 |
Terumo (TRUMY) | Japan | $27.757B | 39.20 |
Zimmer Biomet Holdings (ZBH) | United States | $21.878B | 13.77 |
Baxter (BAX) | United States | $20.540B | 13.93 |
Insulet (PODD) | United States | $16.399B | 68.99 |
Smith & Nephew SNATS (SNN) | United Kingdom | $13.775B | 0.00 |
Bio-Rad Laboratories (BIO) | United States | $9.205B | 30.50 |
Demant (WILYY) | Denmark | $9.197B | 0.00 |
BellRing Brands (BRBR) | United States | $7.646B | 32.33 |
Lantheus Holdings (LNTH) | United States | $7.464B | 17.92 |
ICU Medical (ICUI) | United States | $4.385B | 41.84 |
Haemonetics (HAE) | United States | $3.926B | 19.42 |
TG Therapeutics (TGTX) | United States | $3.854B | 40.80 |
Perrigo (PRGO) | Ireland | $3.848B | 12.16 |
GN Store Nord (GNNDY) | Denmark | $3.656B | 22.03 |
Prestige Consumer Healthcare (PBH) | United States | $3.651B | 18.19 |
Neogen (NEOG) | United States | $3.541B | 37.14 |
Envista Holdings (NVST) | United States | $3.248B | 17.33 |
QuidelOrtho (QDEL) | United States | $3.092B | 19.49 |
Agios Pharmaceuticals (AGIO) | United States | $2.584B | 0.00 |
Maravai LifeSciences Holdings (MRVI) | United States | $2.305B | 0.00 |
Green Thumb Industries (GTBIF) | United States | $2.294B | 38.50 |
LeMaitre Vascular (LMAT) | United States | $2.022B | 53.89 |
AdaptHealth (AHCO) | United States | $1.537B | 11.10 |
Warby Parker (WRBY) | United States | $1.510B | 0.00 |
InMode (INMD) | Israel | $1.433B | 9.12 |
AtriCure (ATRC) | United States | $1.329B | 0.00 |
Owens & Minor (OMI) | United States | $1.237B | 9.55 |
BioLife Solutions (BLFS) | United States | $1.175B | 0.00 |
Verano Holdings (VRNOF) | United States | $1.157B | 0.00 |
Evolus (EOLS) | United States | $1.058B | 0.00 |
PetIQ (PETQ) | United States | $0.918B | 23.28 |
Phibro Animal Health (PAHC) | United States | $0.872B | 18.09 |
National Vision Holdings (EYE) | United States | $0.848B | 26.95 |
Cresco Labs (CRLBF) | United States | $0.830B | 0.00 |
Surmodics (SRDX) | United States | $0.563B | 119.51 |
Quanterix (QTRX) | United States | $0.498B | 0.00 |
VAREX IMAGING (VREX) | United States | $0.472B | 14.23 |
ZimVie (ZIMV) | United States | $0.462B | 42.95 |
Valneva SE (VALN) | France | $0.438B | 0.00 |
Canopy Growth (CGC) | Canada | $0.418B | 0.00 |
Jin Medical (ZJYL) | China | $0.394B | 0.00 |
Cerus (CERS) | United States | $0.382B | 0.00 |
TerrAscend (TSNDF) | Canada | $0.341B | 0.00 |
OraSure Technologies (OSUR) | United States | $0.328B | 8.46 |
Aurora Cannabis (ACB) | Canada | $0.323B | 0.00 |
Biote (BTMD) | United States | $0.320B | 14.77 |
Sanara MedTech (SMTI) | United States | $0.294B | 0.00 |
Viemed Healthcare (VMD) | United States | $0.288B | 30.96 |
Zynex (ZYXI) | United States | $0.253B | 44.28 |
Ayr Wellness (AYRWF) | United States | $0.241B | 0.00 |
Utah Medical Products (UTMD) | United States | $0.234B | 15.56 |
Omeros (OMER) | United States | $0.226B | 0.00 |
MacroGenics (MGNX) | United States | $0.215B | 0.00 |
Organigram Holdings (OGI) | Canada | $0.197B | 0.00 |
High Tide (HITI) | Canada | $0.176B | 73.00 |
FitLife Brands (FTLF) | United States | $0.150B | 20.26 |
Capricor Therapeutics (CAPR) | United States | $0.144B | 0.00 |
Brainsway (BWAY) | Israel | $0.141B | 168.80 |
TriSalus Life Sciences (TLSI) | United States | $0.137B | 0.00 |
Quipt Home Medical (QIPT) | United States | $0.122B | 0.00 |
Rockwell Medical (RMTI) | United States | $0.119B | 0.00 |
Veru (VERU) | United States | $0.119B | 0.00 |
Jushi Holdings (JUSHF) | United States | $0.110B | 0.00 |
Fonar (FONR) | United States | $0.109B | 11.01 |
Oramed Pharmaceuticals (ORMP) | United States | $0.101B | 24.80 |
InterCure (INCR) | Israel | $0.087B | 14.69 |
Zevia PBC (ZVIA) | United States | $0.078B | 0.00 |
Cellectar Biosciences (CLRB) | United States | $0.075B | 0.00 |
Modular Medical (MODD) | United States | $0.074B | 0.00 |
Safety Shot (SHOT) | United States | $0.072B | 0.00 |
Cytosorbents (CTSO) | United States | $0.067B | 0.00 |
MariMed (MRMD) | United States | $0.064B | 0.00 |
Eagle Pharmaceuticals (EGRX) | United States | $0.055B | 3.58 |
Exagen (XGN) | United States | $0.051B | 0.00 |
Bright Green (BGXX) | United States | $0.037B | 0.00 |
Apyx Medical (APYX) | United States | $0.037B | 0.00 |
Allurion Technologies (ALUR) | United States | $0.037B | 0.00 |
ImmuCell (ICCC) | United States | $0.028B | 0.00 |
Meihua Medical Technologies (MHUA) | China | $0.027B | 0.00 |
Nephros (NEPH) | United States | $0.019B | 0.00 |
GlucoTrack (GCTK) | United States | $0.015B | 0.00 |
Flora Growth (FLGC) | United States | $0.014B | 0.00 |
GUARDION HEALTH (GHSI) | United States | $0.013B | 0.00 |
Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
Innovative Eyewear (LUCY) | United States | $0.010B | 0.00 |
Agape ATP (ATPC) | $0.009B | 0.00 | |
NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
Sharps Technology (STSS) | United States | $0.007B | 0.00 |
IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
Senestech (SNES) | United States | $0.002B | 0.00 |
Akanda (AKAN) | United Kingdom | $0.000B | 0.00 |
Smart For Life (SMFL) | United States | $0.000B | 0.00 |
United-Guardian (UG) | United States | $0.000B | 21.14 |
SNDL (SNDL) | Canada | $0.000B | 0.00 |